What question did this study set out to answer?

To identify independent prognostic factors and establish refined survival subgroups in limited-stage and extensive-stage small-cell lung cancer.

September 1, 1990Journal of Clinical Oncology

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

View Full Paper

Ask AI

Bookmark

Authors

KAKathy S. AlbainLoyola University Chicago JCJohn J. CrowleyCancer Research And Biostatistics MLMichael LeBlancFred Hutch Cancer Center

Discussion

Member takes

Implication

Pooled clinical trial analysis reveals distinct prognostic subgroups in small-cell lung cancer, indicating that lactate dehydrogenase and disease extent refine conventional staging.

Key Points

To identify independent prognostic factors and establish refined survival subgroups in limited-stage and extensive-stage small-cell lung cancer.
Analyzed clinical data from 2,580 patients across 10 Southwest Oncology Group trials conducted between 1976 and 1988 (1,363 limited-stage, 1,217 extensive-stage).
Evaluated clinical, demographic, and treatment variables using Cox multivariate proportional hazards models for both disease stages.
Applied recursive partitioning and amalgamation (RPA) analysis to 1,137 patients from recent trials to generate a refined prognostic regression tree.
In limited-stage disease, good performance status, female sex, age <70 years, white race, normal lactate dehydrogenase (LDH), and concurrent chemoradiotherapy were independent favorable predictors of survival.
In extensive-stage disease, normal LDH, intensive multidrug chemotherapy regimens, and a solitary metastatic lesion independently predicted improved survival.
RPA amalgamation established four distinct prognostic subgroups stratified by stage, LDH, pleural effusion, and age, with median survival times of 19.0, 12.5, 10.5, and 6.3 months (P < 0.0001).

Cite This Study

Albain et al. (1990) studied this question.

synapsesocial.com/papers/6a705529f44fa9f079ddf212 https://doi.org/10.1200/jco.1990.8.9.1563

View Full Paper

Ask AI

Bookmark

Implication

Pooled clinical trial analysis reveals distinct prognostic subgroups in small-cell lung cancer, indicating that lactate dehydrogenase and disease extent refine conventional staging.

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

Discussion

Member takes

Implication

Key Points

Cite This Study

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider